Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Classificação em ações #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Preço da ação
$0.25974701
Última sincronização: 2025-01-06
Valor de mercado
$2.04M
Variação (1 dia)
0.74%
Variação (1 ano)
0.00%
País
FR
Negociar Acticor Biotech SAS (ALACT)

Categoria

Rácio P/B de Acticor Biotech SAS (ALACT)
Rácio P/B em September 2026 TTM: -0.57
De acordo com os relatórios financeiros mais recentes e o preço das ações da Acticor Biotech SAS, o rácio P/B atual (TTM) é -0.57. No final de 2022, o rácio P/B era -33.19.
Histórico do rácio P/B da Acticor Biotech SAS de 2010 a 2026
Rácio P/B no final de cada ano
Ano Rácio P/B Alterar
2026 (TTM) -0.57 -91.38%
2023 -6.59 -80.15%
2022 -33.19 -1,126.36%
2021 3.23 -87.62%
2020 26.12 538.96%
2019 4.09 17.85%
2018 3.47 -160.01%
2017 -5.78 -511.84%
2016 1.40 2.83%
2015 1.37 7.92%
2014 1.26 5.23%
2013 1.20 -8.34%
2012 1.31 -12.44%
2011 1.50 -91.22%
2010 17.05 0.00%
Rácio P/B de empresas semelhantes ou concorrentes
Empresa Rácio P/B Diferença do rácio P/B País
6.5144 -1,247.10%
US
7.3983 -1,402.75%
NL
3.9974 -803.89%
AU
8.5918 -1,612.91%
US
- -
CH